Camurus AB (publ) (CAMRF)

Camurus AB (publ) (CAMRF) Healthcare & Pipeline Overview

Camurus AB (publ) is a Swedish pharmaceutical company specializing in developing and commercializing innovative medicines for severe and chronic conditions globally. Leveraging its proprietary drug delivery technologies, the company focuses on therapeutic areas including opioid dependence, chronic pain, and rare endocrine disorders, with a robust pipeline spanning various clinical stages.

What Is the Investment Thesis for CAMRF?

Camurus AB (publ) presents a profile characterized by its focus on specialty and generic drug manufacturing, evidenced by a market capitalization of $3.60B and a P/E ratio of 47.2. The company demonstrates strong operational efficiency with a gross margin of 92.5% and a profit margin of 30.5%, indicating effective cost management and pricing power for its commercialized products like Buvidal and Brixadi. A key value driver is its extensive and diversified pipeline, with several candidates in late-stage clinical trials, such as CAM2029 (Phase III for acromegaly/neuroendocrine tumors) and CAM4072 (Phase III for genetic obesity disorders). Successful progression and commercialization of these assets could significantly expand market reach and revenue streams. The company's global commercialization efforts across Europe, Australia, the US, and Japan provide multiple avenues for market penetration. However, the inherent risks of pharmaceutical development, including potential clinical trial failures, regulatory hurdles, and competitive market dynamics, remain critical factors for consideration. The company does not currently pay a dividend.

Based on FMP financials and quantitative analysis

CAMRF Key Highlights

• Camurus AB (publ) maintains a robust gross margin of 92.5%, significantly above many industry averages, indicating strong control over its cost of goods sold and efficient manufacturing processes for its specialized pharmaceutical products.
• The company demonstrates a solid profit margin of 30.5%, reflecting effective operational management and the ability to convert a substantial portion of its revenue into net income, which is competitive within the specialty pharmaceutical sector.
• With a market capitalization of $3.60B, Camurus AB (publ) is positioned as a mid-sized pharmaceutical entity, providing a balance between established commercial operations and significant growth potential from its developing pipeline.
• The P/E ratio of 47.2 suggests that investors anticipate future growth, likely driven by the company's extensive drug pipeline and potential market expansion for its commercialized treatments for opioid dependence and other severe conditions.
• Camurus AB (publ) employs 238 individuals, indicating a focused and specialized workforce dedicated to research, development, and commercialization within the drug manufacturing industry, supporting its global operations.

Who Are CAMRF's Competitors?

CAMRF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CAMRF's Key Strengths?

• Strong gross margin (92.5%) and profit margin (30.5%) indicate efficient operations and pricing power.
• Established commercial products (Buvidal, Brixadi) addressing a significant public health issue (opioid dependence).
• Extensive and diversified pipeline with several candidates in late-stage clinical trials (e.g., CAM2029, CAM4072).
• Global commercial presence across Europe, Australia, the US, and Japan.
• Focus on severe and chronic conditions, often with high unmet medical needs and potential for premium pricing.

What Are CAMRF's Weaknesses?

• Reliance on a limited number of commercialized products for current revenue generation.
• Significant R&D expenses associated with a broad pipeline, impacting short-term profitability.
• No dividend yield, which may deter income-focused investors.
• The P/E ratio of 47.2 suggests a high valuation relative to current earnings, implying significant future growth expectations.
• As an OTC-traded stock, it may face challenges related to liquidity and investor perception compared to major exchange listings.

What Could Drive CAMRF Stock Higher?

• Successful completion of Phase III clinical trials for CAM2029 (acromegaly, neuroendocrine tumors) and CAM4072 (genetic obesity disorders), potentially leading to regulatory submissions.
• Regulatory approvals and subsequent market launches of pipeline products in key regions like the US, Europe, or Japan, expanding commercialized portfolio.
• Expansion of market penetration and increased sales volumes for Buvidal and Brixadi in existing and new markets for opioid use disorder treatment.
• Positive data readouts from ongoing Phase II clinical trials for candidates such as CAM2032 (prostate cancer) or CAM2043 (Raynaud's phenomenon), advancing them to later stages.
• Strategic partnerships or licensing agreements that could accelerate development, fund R&D, or expand commercial reach for Camurus's drug candidates.

What Are the Key Risks for CAMRF?

• Rich valuation — a P/E of 47.2 runs well above the Healthcare sector’s ~23x, leaving little room for a miss.
• Clinical trial failures or unexpected adverse events for any of the numerous pipeline candidates, leading to significant R&D write-offs and delays in product commercialization.
• Intense competition within the specialty and generic drug manufacturing industry, potentially impacting market share and pricing power for existing and future products.
• Regulatory hurdles, delays in approval processes, or unfavorable decisions from health authorities in key markets, hindering product launches.
• Market access and reimbursement challenges, as payers may impose restrictions or demand lower prices for new therapies, impacting profitability.
• Dependence on the successful commercialization of a limited number of approved products, making the company vulnerable to market shifts or competitive pressures in those specific therapeutic areas.

What Are the Growth Opportunities for CAMRF?

• **Expansion of Opioid Use Disorder (OUD) Treatment Market:** Camurus's Buvidal and Brixadi are buprenorphine injections for opioid dependence. The global OUD treatment market continues to expand due to ongoing public health crises and increased awareness. As of 2026, the demand for long-acting, less frequently administered OUD treatments is significant, offering Camurus an opportunity to increase market share by demonstrating superior patient adherence and convenience. Continued commercialization efforts in existing and new geographies, particularly in the United States and Europe, could drive substantial revenue growth. The market size for OUD treatments is substantial, with a continuous need for effective, accessible, and patient-friendly options.
• **Advancement of CAM2029 for Acromegaly and Neuroendocrine Tumors:** CAM2029 is currently in Phase III clinical trials for acromegaly and neuroendocrine tumors, and Phase II for polycystic liver diseases. Acromegaly and neuroendocrine tumors represent significant orphan drug opportunities with high unmet needs. Successful completion of Phase III trials and subsequent regulatory approval would open access to these specialized markets. The timeline for potential market entry, given its advanced stage, could be within the next few years, positioning Camurus to capture a share of these high-value therapeutic areas. The market for treatments for rare endocrine and oncological conditions, while smaller in patient numbers, often commands premium pricing.
• **Development of CAM4072 for Genetic Obesity Disorders:** CAM4072 is in Phase III clinical trials for the treatment of genetic obesity disorders. Genetic obesity, while a niche area, represents a severe and chronic condition with limited effective treatment options. Successful development and commercialization of CAM4072 could address a significant unmet medical need within a specialized patient population. The market for novel obesity treatments, particularly those targeting genetic causes, is poised for growth as understanding of disease mechanisms improves. A successful launch could establish Camurus as a leader in this emerging therapeutic segment within the next three to five years.
• **Pipeline Diversification into Chronic Pain with CAM2038:** CAM2038 is under development for chronic pain, a pervasive condition affecting millions globally. The chronic pain market is vast, with a continuous need for non-opioid or improved opioid-sparing treatments due to concerns about addiction and side effects. While in an earlier stage of development, successful progression of CAM2038 through clinical trials could tap into a multi-billion dollar market. This diversification would reduce reliance on existing commercial products and expand Camurus's therapeutic footprint, offering a significant long-term growth opportunity over the next five to ten years.
• **Exploration of Rare Disease and Niche Indications:** Camurus's pipeline includes several candidates targeting rare diseases and niche indications, such as CAM2043 for pulmonary arterial hypertension and Raynaud's phenomenon (Phase I/II), and CAM2032 for prostate cancer (Phase II). These areas often benefit from accelerated regulatory pathways and command higher pricing due to the limited patient populations and high unmet needs. Successfully bringing even one of these specialized treatments to market could provide significant revenue streams and reinforce Camurus's reputation as an innovator in complex disease management. These opportunities represent strategic long-term growth avenues, with varying timelines depending on clinical progression.

What Opportunities Does CAMRF Have?

• Successful progression and commercialization of late-stage pipeline assets (CAM2029, CAM4072) into new therapeutic markets.
• Expansion of market share for Buvidal and Brixadi in existing and new geographic regions for opioid use disorder treatment.
• Diversification into large markets like chronic pain (CAM2038) and specialized areas like genetic obesity disorders.
• Potential for strategic partnerships or licensing agreements to accelerate development or expand commercial reach for pipeline products.
• Addressing unmet medical needs in rare diseases and niche indications, which often have expedited regulatory pathways.

What Threats Does CAMRF Face?

• Clinical trial failures or unexpected safety concerns for pipeline candidates, leading to significant R&D write-offs.
• Intense competition from larger pharmaceutical companies with greater resources and established market presence.
• Regulatory hurdles and delays in obtaining marketing approvals in various jurisdictions.
• Pricing pressures and reimbursement challenges from healthcare payers and government agencies.
• Patent expirations or new generic entrants impacting commercialized products in the future.

What Are CAMRF's Competitive Advantages?

• Proprietary drug delivery technologies that enable extended-release formulations, potentially improving patient adherence and outcomes.
• Established commercial products like Buvidal and Brixadi in the opioid use disorder market, providing a revenue base and market presence.
• Extensive and diversified pipeline with several late-stage assets (Phase III), indicating potential for future market exclusivity and revenue streams.
• Specialization in severe and chronic conditions, often with high barriers to entry due to complex R&D and regulatory requirements.
• Global commercialization footprint across Europe, Australia, the US, and Japan, facilitating broader market access for approved therapies.

What Does CAMRF Do?

Camurus AB (publ), founded in 1991 and headquartered in Lund, Sweden, is a pharmaceutical company dedicated to the development and commercialization of advanced medicines for severe and chronic conditions. The company operates across key international markets, including Europe, Australia, the United States, and Japan, addressing significant unmet medical needs. Camurus has established a portfolio of commercialized products, notably Buvidal, a buprenorphine injection approved for the treatment of opioid dependence, and Brixadi, also indicated for opioid use disorder. Additionally, its product offerings include episil oral liquid, a medical device designed to treat inflammatory and painful conditions within the oral cavity. The core of Camurus's strategy lies in its extensive and diversified product pipeline, which features numerous candidates in various stages of clinical development. This pipeline targets a broad spectrum of therapeutic areas, reflecting the company's commitment to innovation in complex disease management. For instance, CAM2038 is under development for chronic pain, while CAM2029 is progressing through Phase III clinical trials for acromegaly and neuroendocrine tumors, and also in Phase II for polycystic liver diseases. Further pipeline assets include CAM2043, which is in Phase I for pulmonary arterial hypertension and Phase II for Raynaud's phenomenon. Other notable candidates include CAM2032 in Phase II for prostate cancer, CAM4072 in Phase III for genetic obesity disorders, CAM4071 in Phase I for endocrine disorders, CAM2047 in Phase I for chemotherapy-induced nausea and vomiting, and CAM2048 in Phase I for postoperative pain. This comprehensive approach underscores Camurus's ambition to bring novel therapeutic solutions to patients worldwide, building on its foundational expertise in pharmaceutical research and development.

What Products and Services Does CAMRF Offer?

• Develop and commercialize medicines for severe and chronic conditions.
• Offer Buvidal, a buprenorphine injection for treating opioid dependence.
• Provide Brixadi for the treatment of opioid use disorder.
• Market episil oral liquid, a medical device for inflammatory and painful oral conditions.
• Conduct Phase III clinical trials for CAM2029 (acromegaly, neuroendocrine tumors) and CAM4072 (genetic obesity disorders).
• Advance CAM2038 for chronic pain and CAM2032 for prostate cancer through clinical development.
• Engage in early-stage research for treatments like CAM2043 (pulmonary arterial hypertension), CAM4071 (endocrine disorder), CAM2047 (chemotherapy-induced nausea), and CAM2048 (postoperative pain).
• Operate internationally across Europe, Australia, the United States, and Japan.

How Does CAMRF Make Money?

• Develop proprietary pharmaceutical products through extensive research and clinical trials.
• Commercialize approved medicines directly or through partnerships in key global markets.
• Generate revenue from the sales of prescription drugs like Buvidal and Brixadi for opioid use disorder.
• Monetize medical devices such as episil oral liquid for oral cavity conditions.
• Invest in a diverse pipeline of drug candidates, aiming for future revenue streams from new product launches.

What Industry Does CAMRF Operate In?

Camurus AB (publ) operates within the highly specialized and competitive Drug Manufacturers - Specialty & Generic industry, a sub-segment of the broader Healthcare sector. This industry is characterized by significant R&D investment, stringent regulatory oversight, and a constant drive for innovation to address unmet medical needs. The market for specialty drugs, particularly in areas like opioid use disorder, chronic pain, and rare endocrine conditions, continues to grow, driven by increasing prevalence of these conditions and advancements in targeted therapies. Camurus positions itself by focusing on proprietary drug delivery technologies and developing novel formulations for severe and chronic conditions. The competitive landscape includes both large multinational pharmaceutical corporations and smaller, agile biotech firms. Camurus differentiates itself through its specific pipeline assets and established commercial products like Buvidal and Brixadi, competing with companies like ALK-Abelló A/S, Livzon Pharmaceutical Group Inc., Shanghai Junshi Biosciences Co., Ltd., and Laboratorios Farmaceuticos Rovi, S.A. The company's ability to navigate complex regulatory pathways and secure market access for its specialized treatments is critical for its sustained growth in this dynamic environment.

Who Are CAMRF's Key Customers?

• Healthcare providers, including hospitals, clinics, and addiction treatment centers, prescribing medications for opioid use disorder.
• Patients suffering from severe and chronic conditions requiring specialized pharmaceutical interventions.
• Specialist physicians treating conditions such as acromegaly, neuroendocrine tumors, and genetic obesity disorders.
• Pharmacies and distributors that supply Camurus's products to healthcare systems.
• Oncology and pain management specialists for pipeline products targeting prostate cancer, chronic pain, and chemotherapy-induced nausea.

Camurus AB (publ) (CAMRF) Valuation Context

Valued at $3.60B, CAMRF is classified as a mid-cap stock. Relative to its peer group, CAMRF's quantitative score of 63/100 is roughly in line with the peer average of 55/100.

CAMRF Revenue & Earnings Trend

In Q1 2026, CAMRF generated $531.3M in top-line revenue, marking a sequential increase of 14.4%. The company recorded net income of $143.3M, with diluted EPS of $2.40. Quarter-over-quarter revenue has been mixed, typical for a mid-cap company operating in Healthcare. Across the four most recent quarters, CAMRF averaged $2.83 in diluted EPS.

Company Profile

Camurus AB (publ) operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Lund, SE. The company is led by CEO Fredrik Tiberg. CAMRF has traded publicly since 2017.

ROE 16%Key Financial Metrics

Return on equity for Camurus AB (publ) stands at 16.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 13.8%, showing how much profit it generates from its asset base. CAMRF trades at a trailing price-to-earnings ratio of 47.23, above the Healthcare sector average of ~23x. Its free cash flow yield is 2.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 11.57 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 2.1%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 5/9Financial Health

Camurus AB (publ)'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 41.61 places it in the safe zone, indicating low near-term bankruptcy risk.

FY2026 estForward Outlook

Wall Street analysts project Camurus AB (publ) revenue of about $2.71B for fiscal 2026, with EPS near $13.78. The estimate reflects 8 contributing analysts.

CAMRF Financials

CAMRF Latest News

CAMRF Analyst Consensus

CAMRF MoonshotScore

Camurus AB (publ) Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources